

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035090 A1

(51) International Patent Classification⁷: **A61K 45/06**,
9/00, A61P 1/04 // A61K 31/4439, 31/4164, 31/341,
31/426

(74) Agents: **ZACCO SWEDEN AB** et al.; P.O. Box 23101,
Sveavägen 170, S-104 35 Stockholm (SE).

(21) International Application Number:
PCT/SE2003/001598

(22) International Filing Date: 15 October 2003 (15.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203065-8 16 October 2002 (16.10.2002) SE

(71) Applicant (for all designated States except US): **OREXO**
AB [SE/SE]; Box 303, S-751 05 Uppsala (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PETTERSSON**,
Anders [SE/SE]; Tysslanda Säteri, S-463 94 Lilla Edet
(SE). **NYSTRÖM**, **Christer** [SE/SE]; Holmvägen 22 B,
S-756 61 Uppsala (SE). **HÅKANSSON**, **Yvonne** [SE/SE];
Holmvägen 22 B, S-756 61 Uppsala (SE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GASTRIC ACID SECRETION INHIBITING COMPOSITION

(57) Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least one pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

GASTRIC ACID SECRETION INHIBITING COMPOSITION

FIELD OF THE INVENTION

5 The present invention relates to a gastric acid secretion inhibiting composition, to a method for its manufacture and to its use in treating conditions which are related to the secretion of gastric acid.

BACKGROUND OF THE INVENTION

10

During the latest decades, much progression has been made in the suppression of acid secretion, an integral part of the treatment of dyspeptic disorders such as gastro-oesophageal reflux disease (GORD), duodenal and gastric ulcers and non-ulcer dyspepsia. Although the pathophysiology of these disorders is not identical, the inhibition of gastric
15 acid secretion is pivotal to healing organic lesions, alleviating symptoms of discomfort and improving the quality of life. Moreover, acid-related damage may underlie the progression to cancers and other late complications of these conditions. Inhibition of acid secretion is also a cornerstone in the treatment regimens aiming for eradication of *Helicobacter pylori* infection.

20

Dyspepsia (acid dyspepsia) is a common disorder. Heartburn is a symptom of dyspepsia. It is estimated that 44% of Americans have heartburn at least once monthly but that only about 25 % of them are seeing the doctor because of their dyspepsia problem. Symptoms associated with dyspepsia are for instance upper abdominal pain/discomfort and heartburn,
25 indigestion, "sour" stomach, and gastro-esophageal reflux.

30

Dyspepsia is a multi-factorial disease and may be associated with organic pathology such as duodenal ulcer, gastric ulcer, esophagitis, Barrett's esophagus or gastro-duodenal inflammation (e.g., *Helicobacter pylori* infection). Dyspepsia also includes conditions
where no organic pathology can be found, e.g., non-ulcer dyspepsia (NUD) or functional dyspepsia.

Dyspepsia can be controlled by administration of medicines that raise the pH in the stomach. Therapeutic agents effective in the treatment of dyspepsia include gastric acid

suppressing agents, such as histamine H₂ receptor antagonists (in the following called H₂ receptor antagonists), acid susceptible proton pump inhibitors, antacids/alginates, anticholinergics and prokinetic agents. They can be distinguished by their mechanism of action, safety profile, and pharmacokinetics. The stomach pathogen *Helicobacter pylori* has been associated with dyspepsia, gastro-duodenal ulcer disease and stomach cancer. The treatment of *H. pylori* infection usually comprises the administration of a combination of acid secretion suppressing agents and one or two antibiotic agents.

The therapeutic effect on dyspepsia-related discomfort and organic lesions when inhibiting acid production by administration of acid secretion-inhibiting drugs is related to the degree of acid inhibition as well as to the onset and duration of action of the particular drug. The majority of patients who have symptomatic acid reflux disease have a normal esophageal mucosa or only a mild degree of oesophagitis. Treatment to relieve symptoms as they occur may be the best way to manage these patients, to whom the speed of symptom relief is of primary importance.

Antacid agents, that is, acid-neutralizing agents, and alginates are the first therapeutic choice in the treatment of mild heartburn. They have a extremely short duration of action but are seen as inexpensive and safe. Antacid agents work locally through a neutralization of gastric acid. Alginates provide some mechanical protection against reflux of gastric acid into the esophagus. The main advantages of antacid agents and alginates are that they provide fast relief of symptoms. The main disadvantage of antacid agents and alginates is their extremely short duration of action, and dosing has to be repeated frequently to keep the patients free of symptoms, further that antacids often do not provide symptom resolution, i.e. complete relief of symptoms. Moreover, these agents are not at all useful in the treatment of acid induced organic lesions, GORD or *Helicobacter pylori* infection.

Several classes of compounds are known which affect the secretion of gastric acid. Among them, acid susceptible proton pump inhibitors, such as the substituted benzimidazoles omeprazole, lansoprazole, rabeprazole and pantoprazole and histamine H₂ receptor antagonists, such as cimetidine, ranitidine and famotidine are the most prominent ones. H₂ receptor and acid susceptible proton pump inhibitors are widely prescribed for reducing gastric acid secretion systemically.

The design of acid suppression therapy requires a detailed understanding of the mechanisms behind the secretion of hydrogen ions, namely the parietal cell and hydrogen-potassium adenosine triphosphate (H^+,K^+ -ATPase) so that these mechanisms can be effectively targeted with pharmacological intervention. Three key factors have been identified in order to achieve an effective pharmacological treatment of acid related disorders (*Dig Dis Sci 1995 vol 40: 24S-49S. Optimizing acid suppression for treatment of acid-related diseases.*):

- 1) Time to onset of action, i.e. the inhibition of acid secretion should occur as rapidly as possible.
 - 2) Degree of acid inhibition, i.e. the intragastric pH should be kept well above 4.
 - 3) Duration of action, i.e. the inhibition of acid secretion should remain virtually complete during 24 hours on the first dose and remain complete during the course of treatment.
- All of these factors must be considered when deciding how to optimize said suppressive therapy. However, several aspects of the parietal cell physiology and the pharmacology/biochemistry of existing pharmaceuticals have to date prevented the achievement of this goal.
- Central to the acid secretory mechanism are the parietal cells of the stomach. These cells secrete hydrogen ions into the gastric lumen under the control of neurocrine, paracrine and endocrine pathways. One of the major paracrine factors is histamine released by the enterochromaffine-like (ECL) cells. The histamine released from the ECL cells stimulates parietal cells to acid secretion via histamin-2(H_2) receptors located on the cell surface. Engagement of these receptors results in cyclic adenosine-3,5-monophosphate (cAMP) elevation and cAMP binding to the regulatory subunit. A variety of proteins will be phosphorylated, all of which will be relevant to activation of secretion. The molecular dissection of this intracellular pathway is far from complete, however, the action of cAMP includes translocation of H^+,K^+ -ATPase into the secretory canaliculus and activation of the KCL transporters, i.e. put the parietal cell into a secretory state.

The first attempts of decreasing acid secretion targeted the paracrine pathway, namely the histamine H_2 receptor activation-induced stimulation of acid secretion. Accordingly, the first class of acid inhibitors was the H_2 receptor antagonists (H_2 blockers), including

compounds such as cimetidine, ranitidine, famotidine and nizatidine. Their mode of action is to antagonize the effects of histamine, i.e. to inhibit the recruitment of proton pumps to the secretory canaliculus and reduce the activity of KCL transport. This will put the parietal cells into a non-secretory state and thereby reduce the output of hydrogen ions (*Dig Dis Sci* 1995, vol 40:3S-23S. Pharmacological aspects of acid secretion).

However, phenomena of acid rebound and tolerance are major drawbacks to the use of these drugs in treating acid related diseases. There is an approximately 50% loss in acid reduction capacity during repeated dosing, which severely restricts the use of this class of drug in the treatment of, for example, GORD (*Aliment Pharmacol Ther* 1990, vol 4: 29-46. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine). Moreover, these agents are not at all useful in the treatment of *Helicobacter pylori* infection, a treatment dependent on an effective and sustained reduction of acid secretion.

Current treatment of acid related disorders is focused on a more direct target, the H^+, K^+ -ATPase ("proton pump") of the active parietal cell. These cells constitute the final acid sources - the acid secretory canaliculus and the acid pump itself. Therefore, drugs designed to inhibit acid secretion at this level show a greater efficacy and specificity. Because proton pump inhibitors (PPIs) act at a step downstream of the parietal cell stimulus, tolerance does not occur with the use of these compounds, in contrast to the H_2 receptor antagonists. Moreover, these drugs hit the final target to which all other pathways converge, the H^+, K^+ -ATPase in the acid space or canaliculus of the stimulated parietal cell.

Individual PPIs are similar with respect to their general structure, which consists of a substituted pyridylmethanesulfinyl benzimidazole. PKa values for these compounds vary from 4.0 to 5.0. All PPIs share the same pharmacological mechanism that is essentially the same: their pKa restricts accumulation of the compound to acid spaces, such as that in the parietal cell. PPI accumulation in the canaliculus of the parietal cell is followed by an acid-dependent activation step whereby the PPI is converted to sulphenic acid or sulphenamides. Formation of these reactive intermediates allows for binding to cysteine residues within the exposed luminal surface of the H^+, K^+ -ATPase. The enzyme is functionally inactivated via the production of covalent disulphide bonds. The inhibition of H^+, K^+ -ATPase by PPIs thus results in a relatively stable inhibition of the enzyme, as *de novo* synthesis of the enzyme is

required to reverse the inhibition. These mechanisms of action is described in *Dig Dis Sci* 1995, vol 40:3S-23S. Pharmacological aspects of acid secretion.

One of the fundamental characteristics of the PPIs is that they are only functional in active
5 parietal cells, i.e. the cells have to be in a secretory state. The reason for this is three-fold.
Firstly, in most parietal cells, the acid space (canaliculus) has a pH of about 1.0. At this pH,
the pKa values of PPIs allow them to accumulate in the parietal cell 1000- to 10,000-fold.
However, at higher pH, for example 3, this accumulation decreases by two orders of
10 magnitude, i.e. to 10- to 100-fold. Thus, the weak base characteristics of the PPIs allow
them to accumulate only when acid is being formed by the parietal cell. This becomes
important when administering PPIs during conditions when the parietal cell is put into a
non-secretory state. Secondly, the conversion of PPI to sulphenic acid or sulphenamide is
an acid-dependent process. Thirdly, the H^+, K^+ -ATPase has to be activated, i.e. the enzyme
has to be inserted into the membrane of the secretory canaliculus, where its cysteine
15 residues can be reached by the sulphenamides (*Pharmacotherapy* 1997 vol 17:22-37.
Proton pump inhibitors and acid related diseases; *Drugs* 1998 vol 56:307-335. Proton pump
inhibitors: pharmacology and rationale for use in gastrointestinal disorders; *Ann NY Acad*
Sci 1997 vol 834:65-76 Structural aspects of the gastric H^+, K^+ -ATPase; *Annu Rev*
Pharmacol Toxicol 1995 vol 35:277-305. The pharmacology of the gastric acid pump).

20 These characteristics of the pharmacology/biochemistry of the PPIs will profoundly affect
the pharmacodynamics of this class of compounds. On one hand, these drugs require an
active enzyme for inhibition and some pumps are not active while the drug is present in the
blood. On the other hand, the PPIs exhibit a relatively short plasma half-life of 60 minutes,
25 and new pumps are synthesized at a rate of 25% per 24 hours.

These facts point to the therapeutic dilemma of PPIs at present. As the compounds are
accumulated and converted in the acidic space of the parietal cell, only those pumps which
are secreting acid will be inhibited. Since the cell has a reserve of inactive pumps and is in
30 the process of synthesizing new pumps, many pumps destined to be active within the next
24 hours will not be inhibited by the first dose. However, the following day, when PPI is
given again, new pumps have been recruited and can be inhibited, and the pumps inhibited
24 hours previously have not been replenished entirely. Therefore, the response to PPIs is

cumulative, reaching a steady state and therapeutic acid inhibition first after at least three consecutive days of treatment.

Thus, the current concept regarding PPIs mechanisms of action is the need for active pumps to mediate their effects. In the resting state, parietal cells produce no acid and the pumps are inactive. The inhibition of acid production by PPIs occurs when these pumps are in the active state, via accumulation in the parietal cell, such that subsequent activation of the drug results in an inhibition of the pump (*Eur J of Gastroenterol Hepatol* 2001 vol 13:S35-S41. Improving on PPI-based therapy of GORD)

In summary, neither class of anti-secretory drugs available today attain the goal for acid control stated above, i.e. of a rapid onset of action, potent inhibition of acid secretion and a sustained duration of action during the course of treatment. This goal is of the utmost importance for the clinical outcome of treatment, as the therapeutic effect is related to the onset, degree and duration of action, i.e. how quickly, how much and for how long the pH is raised in the stomach.

Various combinations of antacid and/or mucosa-protecting agents with agents that reduce acid secretion have been disclosed to be useful in treating dyspepsia.

WO 95/017080 describes a composition for use in the treatment of for instance heartburn comprising an H₂ receptor antagonist, such as famotidine, and an alginate and optionally simethicone (an activated polysiloxane).

EP 338861 A describes a solid pharmaceutical preparation consisting of an antacid and excipients which is proposed to be used in combination with an acid-susceptible proton pump inhibitor or any other substance inhibiting gastric acid secretion. There is no suggestion to combine these substances in a fixed unit dosage form.

US 5244670 A describes an ingestible pharmaceutical composition comprising a substance selected from the group consisting of antacid agents, acid secretion-prevention agents, bismuth-containing agents and their mixtures, and 3-(1-menthoxy)-propane-1,2-diol which is present to provide a cooling sensation to the throat.

WO 97/25066 discloses a pharmaceutical formulation comprising a combination of an acid-susceptible proton pump inhibitor or an H₂ receptor antagonist and one or more antacid agents or alginates.

5 Neither acid-susceptible proton pump inhibitors nor H₂ receptor antagonists, alone or in combination with antacids and/or alginates, provide fully satisfactory quick and lasting relief to patients, to whom the speed of symptom relief is of primary importance but who also desire to be free of symptoms for a longer period of time. Thus, none of the solid pharmaceutical preparations for per-oral administration reported to date, satisfies the basic
10 requirements; rapid onset of acid secretion inhibition, potent reduction of acid secretion and a sustained inhibition of acid secretion.

Furthermore, the use of proton pump inhibitors has a serious shortcoming regarding chemical stability:

15

The substances are extremely acid-labile, which has made special formulations necessary. Normally, the substances are protected *in vivo* by the application of a gastric acid-resistant coating (enteric coating) over the active substance. As such coatings in themselves are acidic (release hydrogen ions), it has been found that it is also necessary to provide some
20 sort of protection *in vitro*, i.e. when the product is stored.

This protection *in vitro* may be arranged such as is described in US 6 183 776 B1 (Depui et al.), where an alkaline-reacting substance is added together with the proton pump inhibitor, and a supplementary protective coating (sub-coat) is applied just under the gastric acid-resistant coating.
25

Another approach is disclosed in WO 00/78284 (US 5,225,202), where the gastric acid-resistant coating is neutralized such that it shows no acid reaction during storage. After swallowing, the hydrogen ions present in the stomach will acidify the coating and thus
30 recreate the acid-protecting properties of the coating *in situ*.

It has now been found that both the problem regarding rapid and long lasting relief of symptoms as well as the chemical instability problem of acid susceptible proton pump inhibitors may be solved by the present invention.

OBJECTS OF THE INVENTION

It is an object of the invention to provide a medicine which provides quick and lasting relief
5 to a patient suffering from conditions related to gastric acid secretion.

It is another object of the invention to provide a method for treating a patient suffering from conditions related to gastric acid secretion which provides quick and lasting relief.

10 Further objects of the invention will be evident from the following short description of the invention, a preferred embodiment thereof, and the appended claims.

SUMMARY OF THE INVENTION

15 The present invention relates to a solid pharmaceutical dosage form for oral administration, which is characterized in that it comprises a H₂ receptor antagonist formulated for a rapid release and a PPI which is formulated for an extended release. In the present dosage form, the rapidly released H₂ receptor antagonist will be rapidly absorbed and inhibit acid secretion by the mechanisms described above. The PPI formulated for delayed and/or
20 extended release will maintain a maximal acid suppression already after the first dose and maintain a maximal acid suppression during the course of treatment.

Acid-susceptible proton pump inhibitors are acid-activated prodrugs that covalently inhibit the gastric H⁺,K⁺-ATPase, the proton-transporting enzyme involved in the production of
25 hydrochloric acid in the stomach. The action of gastric H⁺,K⁺-ATPase represents the final step in the sequence of events resulting in secretion of hydrochloric acid by the parietal cell. Thus inhibition of this enzyme is the most effective and specific means of controlling acid secretion regardless of the nature of the stimulus to secretion. As would be expected with such a mechanism of action, proton pump inhibitors such as omeprazole has been shown to
30 inhibit both basal and stimulated acid secretion. Omeprazole is a weak base which accumulates in the acidic milieu of the secretory membrane of the parietal cell where it undergoes rearrangement in acid to its active sulphenamide form which subsequently reacts with sulphydryl groups of the acid pump.

- In gastric mucosa, the acid-susceptible proton pump is situated in the apical membrane and in the tubovesicles bordering the secretory canaliculus of the parietal cell. Thus, after a single dose, omeprazole rapidly accumulates in the acidic compartment of the secretory membrane where its active sulphenamide form irreversibly binds to the H⁺,K⁺-ATPase.
- 5 The H⁺,K⁺-ATPase situated in the tubovesicles will however not be exposed for activated omeprazole. A major portion of synthesized H⁺,K⁺-ATPase will thus escape blockade after a single omeprazole dose. This may explain why the maximal acid-inhibitory effect of omeprazole is reached only after about five days of treatment.
- 10 H₂ receptor antagonists competitively inhibit the action of histamine on all H₂ receptors, mainly on the surface of the parietal cells. At therapeutic doses, these agents are capable not only of decreasing both basal and nocturnal acid secretion, but also secretion stimulated by food, histamine, insulin and pentagastrin. A single dose of an H₂ receptor antagonist results in maximal acid inhibitory effect already within 2 hours after intake. Furthermore, the acid
- 15 inhibitory effect obtained with high doses of an H₂ receptor antagonist is built up rapidly but has a tendency to fade substantially during the following 2-7 days, while the acid inhibitory effect of omeprazole gradually is built up during the same period of time.
- The present invention is based on the unexpected finding that an almost complete inhibition
- 20 of acid secretion is achieved by the first dose of an acid susceptible proton pump inhibitor administered as an extended release formulation. Furthermore, as only activated proton pumps secreting acid during the time PPI is present in the plasma is expected to be inhibited, it was surprisingly found that a sustained inhibition of acid secretion could be achieved while the parietal cells is put into a non-secretory state by means of the rapidly
- 25 released H₂ receptor antagonist.
- Thus, according to the invention, there is provided an oral pharmaceutical dosage form comprising pharmacologically effective amounts of an acid-susceptible proton pump inhibitor or a salt thereof, and an H₂ receptor antagonist or a salt thereof, and a
- 30 pharmaceutically acceptable excipients resulting in delayed and/or extended release of the proton pump inhibitor. The terms "proton pump inhibitor" and "H₂ receptor antagonist" include their isomers, such as enantiomers of proton pump inhibitors, as well as pharmaceutically acceptable salts of such isomers.

The invention is especially suitable for "on demand" treatment of gastro-esophageal reflux complaints e.g. heartburn, where potent acid reduction is needed for a shorter period of time and where a rapid onset of action is most important and a maximal acid reduction is to prefer. The maximal acid inhibitory effect would be able to be maintained during a 7 days
5 period by the elimination of the "fade-off" phenomenon seen after H2-blocker given alone. This will be important in order to reduce the time for the treatment of stomach ulcers, acid-related lesions in the esophagus and *Helicobacter pylori* eradication.

To overcome the previously mentioned problems associated with the proton pump
10 inhibitors, the invention comprises three parts:

1) By formulating the proton pump inhibitor into a composition which releases active substance with a delayed effect (delayed release) and/or with a prolonged effect (extended release), a composition is obtained which acts completely opposite to what has been desired
15 up to now regarding a rapid onset of the effect. However, a new type of protection for these acid-labile pharmaceutical substances is provided.

This type of release-controlled composition is well-known to those skilled in the art and has a number of different designations.
20

In the present specification, the expression "extended release" is used as a synonym to "prolonged release" and "sustained release". Irrespective of which expression is used, the common function is that the release of the active substance is retarded and extended over a longer time. This is normally obtained by either providing a core of active substance with a
25 coating or membrane of suitable auxiliary agents which control the release, or by incorporating the active substance in a matrix of suitable auxiliary agents.

The expression "delayed release" is used in the present specification to describe compositions which do not release active substance immediately. The start of the release is
30 thus displaced to the small intestine or large intestine. This type of composition is normally obtained by providing a core of active substance with a coating or membrane which is changed during the transport in the gastro-intestinal tract by the changes in pH encountered by the composition, or by a change in the coating as a function of the time when the composition is in contact with body fluids. The present type of composition is not to be

confused with gastric acid-resistant compositions ("non-enteric release), which are only intended to protect the composition from hydrogen ions or, alternatively, to protect the patient from a deleterious effect of the medical compound on the stomach.

- 5 The expressions "controlled release" and "modified release" may also be used to describe this part of the invention, but they constitute more collective designations which do not specifically describe the present type of release mechanisms.

10 All these types of designations, principles for formulation and suitable auxiliary agents are well-known to those skilled in the art, and reference is here made to the manual "Pharmaceutics. The Science of Dosage Form Design", 1st edition; Ed. M.E. Aulton, Churchill Livingstone, Edinburgh 1988, which is hereby incorporated by reference. Reference is especially made to pages 289-305.

- 15 It is clear that the basic composition hereby provided may be combined with further additions of auxiliary agents. Thus, for example, the proton pump inhibitor may be blended with an alkaline reacting substance to neutralize the small amount of hydrogen ions which may pass through the membrane or matrix structures during the passage through the stomach. This measure is not strictly necessary, but leads to a more perfect composition. In
20 the same manner, a gastric acid-resistant coating may be provided on the exterior side of the membrane or matrix part of the composition. In a further embodiment, these two formulation measures may be used at the same time.

- 2) The problem of a too slow onset of the increase in pH is not obviously solved by further
25 retarding or time-expanding the release. However, it has now turned out that it is possible to administer an H₂ receptor antagonist having a rapid onset of effect (obtained through a rapid release), without compromise the onset of action of the subsequently released acid susceptible proton pump inhibitor. This was unexpected since an important feature of PPIs is the need for active pumps to mediate their effects. During influence of an H₂ receptor
30 antagonist, the parietal cells are put into a resting state. In the resting state, parietal cells produce no acid and the pumps are inactive. The inhibition of acid production by PPIs occurs only when these pumps are in the active state, via accumulation in the parietal cells, such that subsequent activation of the drug results in an inhibition of the pump. Thus, the present invention provides a novel pharmacological composition utilizing the rapid

inhibition of acid secretion from a histamine 2 receptor antagonist without offsetting the effect of the concomitantly administered PPI.

- 3) From the current knowledge of PPI mode of action and the biochemistry of H^+ , K^+ - ATPase, it is not obvious how to achieve maximal inhibition of acid secretion with the first dose of a PPI (wide supra).

However, it has now turned out that expanding the time during which PPI is released results in an unexpected efficient first dose inhibition of acid secretion. By extend the time for PPI present in the blood, newly synthesized pumps will be continuously inactivated. This was unexpected, as following the initial inhibition of the pump, the pH in the secretory space would rise and the drug will deprotonate and diffuse back out of the canaliculus. Furthermore, the second clearly essential step in the the PPIs action , the acid-catalysed conversion into the active sulphenamide, would not take place.

- The combination described here may be obtained in two ways. Firstly, a separate dose having a delayed/extended release of the proton pump inhibitor may be administered concurrently with a separate dose of the H2 receptor antagonist. Alternatively, these two substances having different release profiles may be combined into the same preparation. A number of examples will illustrate how this is suitably arranged.

Thus, the present invention provides a sustained acid suppression already after the first dose. This cannot be attained by the products proposed by the prior art:

H2 blockers are only active during the first 6-8 hours.

- H2 blockers + antacids give a rapid onset, but are only active for 6-8 hours

PPIs give no action at all after the first dose.

PPIs + antacids are active for about one hour through the antacid effect.

PPI enantiomer will not reach its full potential after the first dose.

PPI slow release alone will give an effect first after 5-6 hours

30

Thus, the present invention provides an important improvement over the formulations of the prior art. This improved effect is considered to be due to the unexpected clinical/physiological effect attained through he unique preparation of the invention, i.e. the delayed/extended effect of the PPI in combination with the rapid release of the H2 blocker.

Some patent publications are known which disclose combinations of a proton pump inhibitor and compositions for delayed release, and reference may here be made to US 6,132,768, US 6,274,173 B1 and DE 199 25 710 A1. These references are directed to
5 increasing the stability of proton pump inhibitors against degradation and discoloration caused by hydrogen ions. However, they do not teach anything about any combination of a proton pump inhibitor and an H2 receptor antagonist and the unexpected advantages attained thereby.

10 Furthermore, a gastric acid secretion inhibiting composition is known from the international patent application PCT/SE02/00757. This composition comprises a combination of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist, but no mention is made of the excipient system of the present invention and its unexpected advantages.

15 According to the invention, there is provided an oral dosage form comprising an H2 receptor antagonist in an amount effective to reduce the acidity in the stomach after administration and an acid-susceptible proton pump inhibitor in an amount effective to sustain the low acidity effected by the H2 receptor antagonist over an extended period of time. It is preferred for the pharmacologically effective amounts to be amounts capable of
20 raising gastric pH to above 3 within 2 hours from administration and to keep it above 3 for at least 4 hours, preferably for at least 8 hours. It is more preferred for said pharmacologically effective amounts to be amounts capable of raising gastric pH to above 4 within two hours after administration and to keep it above 4 for at least 8 hours, more preferred for at least 16 hours.

25

According to a first preferred aspect of the invention the H2 receptor antagonist is provided in an amount which is capable of providing at least 80% of maximal reduction, more preferred at least 95% of maximal reduction, of the acidity in the stomach within about two hours. "Maximal reduction" is the reduction of acidity which can be maximally obtained by
30 administering an H2 receptor antagonist alone in therapeutically accepted amounts, that is, in amounts in which such drugs are administered in the art. The term "H2 receptor antagonist(s)" as used herein includes all agents that substantially inhibit or block the secretion of gastric acid by binding to histamine type 2 receptors in the stomach. At therapeutic doses such H2 receptor antagonists are capable not only of decreasing basal and

nocturnal acid secretion, but also secretion stimulated by food, histamine, insulin and pentagastrin. Exemplary H₂ receptor antagonists according to the invention are cimetidine, ranitidine, nizatidine and famotidine which are normally used in the form of their pharmacologically acceptable salts, in particular hydrochlorides. The dosage form of the invention preferably comprises from 1 mg to 800 mg of H₂ receptor antagonist or salt thereof, more preferred from 5 mg to 400 mg.

According to a second preferred aspect of the invention the acid-susceptible proton inhibitor is provided in an amount which is capable of maintaining the low acidity effected by the histamine H₂ antagonist over at least 6 hours. Acid-susceptible proton pump inhibitors are rapidly taking market share from H₂ receptor antagonists. The term "acid-susceptible proton pump inhibitor(s)", as used herein, comprises benzimidazole derivatives having substantial H⁺,K⁺-ATPase inhibiting activity, in particular omeprazole, pantoprazole, lansoprazole, rabeprazole, pariprazole, leminoprazole and their pharmaceutically acceptable salts and enantiomers and salts of enantiomers, but include also the other compounds disclosed on pages 7-11 of WO 97/25066 which are hereby incorporated by reference as well as those disclosed in EP 005 129 A1, EP 174 726 A1, EP 166 287 A1, GB 2 163 747, WO 90/06925, WO91/19711, WO91/19712, WO94/27988, WO95/01977.

Thus the dosage form of the invention comprises preferably from 1 mg to 100 mg, more preferred from 5 mg to 50 mg, per single dose of an acid-susceptible proton pump inhibitor or a salt thereof. The acid-susceptible proton pump inhibitor or salt thereof is separated from the H₂ receptor antagonist by the formulation principle, where only the proton pump inhibitor is coated by the membrane or incorporated in a matrix for the purpose of delayed and/or extended release.

According to a third preferred aspect of the invention the H₂ receptor antagonist formulated for rapid release and the acid-susceptible proton pump inhibitor formulated for delayed and/or extended release need not to be comprised by the same pharmaceutical composition but may be administered separately but within a narrow time interval, such as a time interval of one hour, in particular a time interval of 30 min, most preferred a time interval of 10 min. Thus is disclosed a corresponding dose regimen for separate but joint

administration of an acid-susceptible proton pump inhibitor and an H₂ receptor antagonist to treat a condition related to gastric acid secretion.

5 The oral dosage form of the invention thus comprises an acid-susceptible proton pump inhibitor formulated for delayed and/or extended release, an H₂ receptor antagonist formulated for rapid release and, optionally, a gastric acid-suppressing agent and/or an alginate. Preferably, the dosage form of the invention comprises from 100 mg to 1000 mg of antacid agent and/or alginate. The antacid agent of the invention comprises one or
10 several of aluminum hydroxide, calcium carbonate, magnesium carbonate, basic magnesium carbonate, magnesium hydroxide, magnesium oxide and sodium hydrogen carbonate.

Due to the fact that acid-susceptible proton pump inhibitors are generally sensitive to acid (acid-susceptible proton pump inhibitors) they need to be administered in a form which
15 protects them from degradation in the stomach to make them pass into the small intestine where they are absorbed. In this new invention, this is largely solved by the use of excipients for delayed and/or extended release which offers protection, without the known disadvantage of enteric coating layers (i.e. liberation of hydrogen ions, that will increase the degradation rate of the proton pump inhibitors). H₂ receptor antagonists, on the other hand,
20 can be administered without such protection. According to a further preferred aspect of the invention, compositions can be adapted to suit the purpose of the present invention are among those disclosed in WO 97/25066.

The oral dosage forms of WO 97/25066 comprise an acid-susceptible proton pump
25 inhibitor in an amount similar or identical to that used in the composition of the present invention, and one or several antacid agents and/or alginate(s). The adaptation of the compositions of WO 97/25066 essentially consists firstly, in adding the membrane – or matrix system to the part of the formulation that contains the proton pump inhibitor and
secondly, in substituting a pharmacologically effective amount of an H₂ receptor antagonist
30 for a portion of or the entire amount of the antacid agent(s) and/or alginate.

According to the invention, there is provided an oral, multiple-unit tableted dosage form comprising an acid-susceptible proton pump inhibitor in individually delayed/extended release coated units optionally coated with an enteric coating layer in combination with an

H2 receptor antagonist in the form of a powder or granules compressed into a tablet. The enteric coating layer(s) covering the individual units of the acid-susceptible proton pump inhibitor has properties such that the compression of the units into a tablet does not significantly affect the acid resistance of the individually coated units. Furthermore, the multiple unit tableted dosage form provides a good stability to the active substances during long-term storage.

According to the invention, there is also provided a multiple-unit tableted dosage form, which is divisible and easy to handle. Such a multiple-unit tableted dosage form comprises delayed/extended release coated pellets of an acid-susceptible proton pump inhibitor optionally coated with an enteric coating layer compacted with a powdery H2 receptor antagonist. This dosage form may also contain effervescent components for making it disintegrate rapidly when put into water. The pH of the aqueous phase must then be made slightly acidic to prevent dissolution of any present enteric layer. This dosage form can be given to patients with swallowing disorders and in pediatrics. Such a suspension of dispersed units/pellets of appropriate size can be used for oral administration and also for feeding through a naso-gastric tube.

According to the invention, there is also provided a tablet preparation comprising an acid-susceptible proton pump inhibitor in admixture with tablet excipients forming a tablet core which is coated with excipients for delayed and/or extended release, and a separate layer surrounding the tablet core. The surrounding layer comprises an H2 receptor antagonist in admixture with a pharmaceutical excipient. Optionally a separating layer is applied on the tablet core before the core is covered with the coating. A further option is than to also apply, on top of the other coats, an enteric coating layer. Alternatively, the prepared tablet is sectioned in separate layers, each one comprising different active substances. One of the layers, preferably the innermost layer (core), comprises the acid-susceptible proton pump inhibitor in the form of coated pellets in admixture with pharmaceutical excipients and the other layer(s) comprise(s) the histamine H2-antagonist(s), respectively in admixture with pharmaceutical excipient(s). Optionally the two layers are separated by a separating layer to prevent tacking between the two layers. The coated core, comprising the acid-susceptible proton pump inhibitor may also advantageously be coated with an enteric layer by following, for instance, procedures disclosed in WO 00/78284, which is incorporated herein by reference.

According to the invention, the acid-susceptible proton pump inhibitor in the form of coated pellets may be mixed with histamine H₂-antagonist(s) and optionally pharmaceutical excipient(s) to be administered in a sachet intended for oral administration
5 after dispersion in a slightly acidic aqueous solution.

It is thus preferred for the dosage form of the invention to comprise the acid-susceptible proton pump inhibitor or a salt thereof protected by a coating layer for delayed and/or extended release and optionally also an enteric coating layer. Preferably the dosage form of
10 the invention comprises two concentric layers optionally separated by one or more separating layer(s), one layer comprising said acid-susceptible proton pump inhibitor or salt thereof, the other layer comprising said H₂ receptor antagonist or salt thereof.

The inner layer comprises the acid-susceptible proton pump inhibitor or a salt thereof and
15 the outer layer comprises the H₂ receptor antagonist or a salt thereof. According to a preferred aspect the outer layer comprises a disintegrant. The oral dosage form of the invention may take different shapes, such as a tablet, a capsule, a divided powder/pellet formulation, and the like.

20 Further, the proton pump-containing part of the formulations have above been described to exert their delayed and/or extended release effect by applying coatings to a core material of the proton pump inhibitor. However, another approach is instead to exchange the coating layer(s), i.e. the membrane system to a matrix system. The excipients are then chosen to form a lipid or water insoluble matrix. The function of the matrix is then to exert an
25 extended release of the proton pump inhibitor.

According to the invention, there is also disclosed a method for the manufacture of an oral tableted dosage form comprising amounts of an acid-susceptible proton pump inhibitor or a salt thereof and an H₂ receptor antagonist or a salt thereof pharmacologically effective in
30 treating a condition related to dyspepsia, the method comprising forming a first layer comprising said acid-susceptible proton pump inhibitor or salt thereof, a coating of excipients for delayed and/or extended release and optionally an enteric coating surrounding said first layer, and a second layer comprising said H₂ receptor antagonist or salt thereof surrounding said first layer and said coating. Also disclosed is a method for the

- manufacture of an oral dosage form comprising amounts of an acid-susceptible proton pump inhibitor or a salt thereof and an H₂ receptor antagonist or a salt thereof pharmacologically effective in treating a condition related to dyspepsia, the method comprising forming pellets comprising said acid-susceptible proton pump inhibitor or salt thereof, covering said pellets with the above mentioned coatings, and mixing said pellets with a carrier comprising said H₂ receptor antagonist or salt thereof; the carrier optionally comprising a disintegrant. The aforementioned methods of the invention further comprise a final tablet forming step, optionally followed by a film-covering step.
- 10 Another method for the manufacture of the oral dosage form of the invention comprises filling a capsule capable of disintegrating in gastrointestinal fluids to release its contents with the mixture comprising coated proton pump inhibitor pellets and a H₂ receptor antagonist in powdery or granular form.
- 15 Regarding the methods for the manufacture, the proton pump-containing part of the formulations have above been described to exert their delayed and/or extended release effect by applying coatings to a core material of the proton pump inhibitor. However, another approach is instead to exchange the coating layer(s), i.e. the membrane system to a matrix system. The excipients are then chosen to form a lipid or water insoluble matrix.
- 20 The function of the matrix is then to exert an extended release of the proton pump inhibitor.

The use of the pharmaceutical dosage form of the invention is however not restricted to provide quick and lasting relief to a patient suffering from conditions related to gastric acid secretion. The rapid onset of inhibition of gastric acid secretion combined with the maintenance of inhibition as long as desired (by repeated administration of a composition comprising an acid-susceptible proton pump inhibitor, preferably by repeated administration of the composition of the invention) can be expected to have a positive effect on the healing of gastric- and duodenal- ulcers and esophagitis for which the maintenance of intra-gastric pH above 4 for a maximal duration is acknowledged (Huang J Q and Hunt R H, pH, healing rate and symptom relief in patients with GERD, *Yale J Biol Med* 1999, 72:181-94). The composition of the invention thus is also preferred for maintaining gastric pH above 4 for extended periods of time, such as 4 hours and more.

The dosage form of the invention can also be used, in association with one or more antibiotic agent(s), for the eradication of *Helicobacter pylori*.

5 According to the invention, there is also disclosed a method of treating disorders associated with gastric acid secretion, the method comprising the administration of the dosage form of the invention or the concomitant administration of two separate oral dosage forms, one comprising a pharmacologically effective amount of an acid-susceptible proton pump inhibitor or a salt thereof, formulated for delayed and/or extended release, the other comprising a pharmacologically effective amount of an H₂ receptor antagonist or a salt thereof, formulated for rapid release.
10

Furthermore, according to the invention, there is disclosed a method of treating an infection by *Helicobacter pylori*, comprising the administration of the dosage form of the invention or the concomitant administration of two separate oral dosage forms, one comprising a
15 pharmacologically effective amount of an acid-susceptible proton inhibitor or a salt thereof, the other comprising a pharmacologically effective amount of an H₂ receptor antagonist or a salt thereof, in association with the administration of one or more antibiotic agent(s) effective against *H. pylori*.

20 It is preferred for the aforementioned methods of treatment according to the invention to comprise a dose regimen capable of maintaining gastric pH above 4 for at least 95% of the time period starting at 2 hours from the administration of the first dose and extending until 6 hours from the administration of the last dose, in particular a regimen wherein the time period is one week or more, preferably two weeks or more, even more preferred four weeks
25 or more. Also preferred in this context is a dose regimen capable of maintaining gastric pH above 3 for at least 95% of the time period starting at 2 hours from the administration of the first dose and extending until 6 hours from the administration of the last dose, in particular for four weeks or more.

30 The invention will now be described in greater detail by reference to a number of preferred but not limiting embodiments illustrated in a drawing.

BRIEF DESCRIPTION OF THE DRAWINGS

35 Figures 1-4 of the drawings are schematic cross sections illustrating:

- Fig. 1 a multiple unit tableted dosage form comprising an acid-susceptible proton pump inhibitor in the form of delayed and/or extended release coated pellets in admixture with an H₂-receptor antagonist dispersed in a pharmaceutical carrier;
- Fig. 2 a tableted dosage form consisting of two halves, one of which comprises delayed and/or extended release coating-covered pellets of an acid-susceptible proton pump inhibitor in admixture with excipients whereas the other comprises an H₂ receptor antagonist in admixture with excipients;
- Fig. 3 a multiple-layered tableted dosage form comprising an acid-susceptible proton pump inhibitor in a core surrounded by a delayed and/or extended release coating layer and a layer containing an H₂ receptor antagonist dispersed in a pharmaceutical carrier surrounding the core;
- Fig. 4 a capsule dosage form containing an acid-susceptible proton pump inhibitor in delayed and/or extended release coating-covered pellets in admixture with an H₂ receptor antagonist and pharmaceutical excipients;

DESCRIPTION OF PREFERRED EMBODIMENTS

Multiple-unit tableted dosage form: The multiple-unit tableted dosage form of the invention illustrated in Fig. 1 consists of a tablet body 1 optionally covered by a film layer 3 and small pellets 2 distributed at random in the tablet body 1. The pellets 2 contain an acid-susceptible proton pump inhibitor in form of the racemate, an alkaline salt or one of its enantiomers. The individual units 2 (small beads, granules or pellets) containing the acid-susceptible proton pump inhibitor and optionally containing alkaline substances, are coated with a layer(s) possessing delayed release and/or extended release and optionally an additional enteric coating layer. The coated units, 2 are then mixed with the H₂ receptor antagonist and conventional tablet excipients forming, in combination, the tablet body 1. The H₂ receptor antagonist and tablet excipients may be dry mixed or wet mixed into granules. The mixture of coated layered units, H₂ receptor antagonist and excipients are

compressed into the multiple unit tableted dosage forms. By the expression "individual units" is meant small beads, granules or pellets, in the following referred to as proton pump inhibitor pellets. In yet another embodiment of the invention, also the H₂ receptor antagonist is coated onto the "individual units". Then the H₂ receptor antagonist must be positioned in a peripheral position in relation to the coating layers for delayed and/or extended release and enteric release, in order to be rapidly released in the gastro-intestinal tract. In compressing the mixture into tablets, care must be taken not to significantly affect the acid resistance of the coated pellets. In regard of the core material for coating layered pellets comprising an acid-susceptible proton pump inhibitor reference is made to WO 97/25066, page 13, second to last paragraph, to page 15, end of second paragraph, which are hereby incorporated by reference. In regard of the coating layer(s) exerting the delayed and/or extended release reference is made to US6274173, which are hereby incorporated as reference. Reference is also made to "Pharmaceutics. The Science of Dosage Form Design.", 1st edition; Ed. M.E. Aulton, Churchill Livingstone, Edinburgh 1988. Reference is then especially made to pages 289-305. In regard of the enteric coating layer(s) reference is made to WO 97/25066, page 15, second to last paragraph, to page 18, end of second paragraph, which are hereby incorporated by reference. The acid-susceptible proton pump inhibitor pellets covered with layers for delayed and/or extended release and optionally an enteric coating layer(s) may be further covered with one or more over-coating layers. In regard of such over-coating layer(s) reference is made to WO 97/25066, page 18, last paragraph, to page 19, end of first paragraph, which are hereby incorporated by reference. The H₂ receptor antagonist is dry mixed with inactive excipients such as filler, binders, disintegrants, and other pharmaceutically acceptable additives. The mixture is wet massed with a granulation liquid. The wet mass is dried preferably to a loss on drying of less than 3% by weight. Then the dry mass is milled to a suitable size for granules, preferably smaller than 1 mm. Suitable inactive excipients are, for instance, mannitol, corn starch, potato starch, low substituted hydroxypropyl cellulose, microcrystalline cellulose and crosslinked polyvinylpyrrolidone. The dry mixture comprising the H₂ receptor antagonist may be mixed with a suitable granulation liquid comprising, for instance, hydroxypropylcellulose or polyvinyl-pyrrolidone dissolved in water or alcohol or their mixtures. Alternatively the H₂ receptor antagonist is dry mixed with pharmaceutically acceptable excipients (see *supra*). As mentioned above, in another embodiment of the invention the H₂ receptor antagonist can be coated onto the small units, 2, rather than

mixed with excipients to form the tablet body, 1. Irrespective of how the H₂ receptor antagonist is incorporated it should possess a rapid release.

5 Multi-unit tablets: The coated layered pellets comprising an acid-susceptible proton pump inhibitor are mixed with the H₂ receptor antagonist granules or with the prepared dry mixture comprising the H₂ receptor antagonist. The mixture is admixed with lubricant(s) and compressed into a multiple unit tableted dosage form. Suitable lubricants for the tableting process are, for instance, sodium stearyl fumarate, magnesium stearate and talc. The compressed tablets are optionally covered with film-forming agent(s) to obtain a
10 smooth surface. Such a coating layer may further comprise additives such as anti-tacking agents, colorants and pigments or other additives.

The fraction of coated pellets preferably constitutes less than 60% by weight of the total tablet weight. The preferred multiple-unit table formulation thus consists of delayed and/or
15 extended release coated layered pellets optionally coated with an enteric coating layer, comprising the acid-susceptible proton pump inhibitor, optionally in admixture with alkaline reacting compound(s), compressed into tablets with the prepared H₂ receptor antagonist/excipient(s) mixture. The optional enteric coating layer(s) make(s) the pellets of the dosage form insoluble in acidic media but disintegrating/ dissolving in near neutral to
20 alkaline media, such as the gastric fluid present in the proximal part of the small intestine where the dissolution and uptake of the acid-susceptible proton pump inhibitor is desired. The delayed release coating layer, will then start to release the acid susceptible proton pump inhibitor after a certain time period in the gastrointestinal tract or at a certain pH, reached at some position in the intestine or colon. The extended release coating layer will
25 extend the release of the proton pump inhibitor in order to result in drug absorption during several hours. The delayed and/or extended release coated proton pump inhibitor pellets may also be covered with an overcoating layer before being formulated into tablets, and they may also contain one or more separating layer(s) in between the core material and the other layers.

30

Process for making multi-unit tablets: The process for the manufacture of this dosage form represents a further aspect of the invention. After formulating the pellets by dry mixing (ordered mixture), spray coating or layering of the acid-susceptible proton pump inhibitor onto seeds, or by extrusion/spheronization or granulation, the pellets are first optionally

covered with the separating layer(s) and then covered with the delayed and/or extended release layer(s) and then optionally covered with the enteric coating layer(s). The coating is carried out as described above and in the accompanying examples. The preparation of the H2 receptor antagonist mixture is also described in the examples. Optionally the H2 receptor antagonist can be coated onto the already existing layers comprising delayed and/or extended release layer(s) and enteric coating layer.

The coated pellets, with or without an overcoat, are mixed with the prepared H2 receptor antagonist granules or dry powder, tablet excipients and other pharmaceutically acceptable additives and compressed into tablets. Alternatively, the coated proton pump inhibitor pellets may be covered by a second layer containing the H2 receptor antagonist as described in the following examples. Furthermore, as illustrated in Fig. 2, the coated pellets 4 may be intimately mixed with excipients 5 and pre-compressed whereafter the H2 receptor antagonist preparation 7 is added and the entire tablet mass finally compressed into a tablet, optionally with film-forming agent(s) 6 to obtain a smooth surface. As a further alternative illustrated in Fig. 3, the acid-susceptible proton pump inhibitor in the form of a powder may be mixed with tablet excipients and compressed into a tablet 8 which is optionally covered with a separating layer and thereafter covered with delayed and/or extended release coating 9. Optionally, an enteric coating layer is applied. The thus produced tablet core is subsequently press-coated with the H2 receptor antagonist preparation 10. Finally the table may be covered with a tablet coat 11 to obtain a smooth surface.

It is also possible to fill the acid-susceptible proton pump inhibitor in form of coated layered pellets in a sachet together with H2 receptor antagonist and optionally mixed with excipients.

Fig. 4 illustrates a hard gelatin capsule 16 filled with the uncompressed core material 14, 15 of the embodiment of Fig. 1.

30

In the examples given (Fig 1, 2, 3 and 4) the terms coating, coating layer or layer have been used. These terms are exchangeable and also identical to the term membrane. Irrespective of the nomenclature they have in common that they correspond to more or less continuous

phases of excipient materials applied by e.g. spraying onto a core material. Due to the nature of the processing these membranes are relatively thin with regard to thickness.

5 Suitable excipient materials for forming coatings layers (or membranes) for delayed and/or extended release are non-polymeric-or polymeric materials such as calcium phosphate, ethyl cellulose, methacrylate copolymer, polyamide, polyethylene, polyvinyl alcohol or polyvinyl acetate.

10 Further, the proton pump-containing part of the formulations (2 in Fig 1, 4 in Fig 2, 8 in Fig 3 and 15 in Fig 4) have above been described to exert their delayed and/or extended release effect by applying coatings to a core material of the proton pump inhibitor. However, another approach is instead to exchange the coating layer(s), i.e. the membrane system to a matrix system. The excipients are then chosen to form a lipid or water insoluble matrix. The function of the matrix is then to exert an extended release of the proton pump inhibitor.

15 Suitable matrix forming excipients are non-polymeric-or polymeric materials such as calcium phosphate, ethyl cellulose, methacrylate copolymer, polyamide, polyethylene or polyvinyl acetate, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, microcrystalline waxes, mono- and triglycerides, polyethylene glycol or polyethylene glycol monostearate and most preferably carnauba wax, cetyl alcohol, hydrogenated

20 vegetable oils, microcrystalline waxes, mono- and triglycerides, polyethylene glycol or polyethylene glycol monostearate. In order to obtain an optimal release rate, hydrophilic, pore-forming excipients can be optionally added. Suitable hydrophilic, pore forming materials are alginates, carbopol, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose or methylcellulose.

25

In general, the methods of WO 97/25066 for making oral pharmaceutical dosage forms comprising an acid susceptible proton pump inhibitor and an antacid agent or alginate can be adapted to suit the purpose of the present invention by firstly, adding the membrane- or matrix system to the part of the formulation that contains the proton pump inhibitor and

30 secondly, by substituting part or the entire amount of antacid agent or alginate by a pharmacologically effective amount of an H₂ receptor antagonist, the remainder of the antacid agent or alginate (if substitution is not 1:1 by weight) being omitted or substituted by excipients like microcrystalline cellulose, silica, lactose, mannitol, ant the like.

USE OF THE DOSAGE FORMS ACCORDING TO THE INVENTION.

The dosage forms according to the invention are especially advantageous in the treatment of dyspepsia and other gastrointestinal disorders related to the production of gastric acid to provide quick and lasting relief from symptoms. The dosage forms are administered once or several times a day. The typical daily dose of the acid-susceptible proton pump inhibitor and the H₂ receptor antagonist will depend on various factors such as individual requirements of patients, the mode of administration, and the particular condition to be treated. In general each dosage form will comprise from 1 mg to 100 mg of acid-susceptible proton pump inhibitor and from 1 to 800 mg of the H₂ receptor antagonist. Preferably each dosage form will comprise from 5 to 50 mg of the acid-susceptible proton pump inhibitor and from 5 to 200 mg of the H₂ receptor antagonist. The multiple unit tablet preparation is also suitable for dispersion in water, which has been made slightly acidic by the addition of citric acid.

15

EXAMPLE 1. Multiple-unit tableted dosage form comprising magnesium omeprazole and cimetidine hydrochloride; batch size 400 tablets. For omeprazole Mg-salt pellet production (core material, separating layer, enteric coating layer and over-coating layer, see WO 97/25066, p. 22-23 under respective headings), see WO 97/25066, first two paragraphs, all of which is hereby incorporated by reference. The extended release layer is applied, by a coating process, in between the separation layer and the enteric coating layer, in accordance with what is described in patent US6274173, Example 1-4, using ethyl cellulose or polyvinyl acetate as extended release forming excipients, the information under which is hereby incorporated as reference.

25

Tablets

Prepared pellets comprising omeprazole Mg-salt	31.3 g
Microcrystalline cellulose	300.0 g
Cimetidine hydrochloride	40.0 g
Potato starch	50.0 g
Water	200.0 g
PVP crosslinked	38.0 g
Sodium stearyl fumarate	4.6 g

A small amount of the potato starch is dissolved in purified hot water to form the granulation liquid. Cimetidine hydrochloride, the rest of potato starch and microcrystalline cellulose are dry mixed. The granulation liquid is added to the dry mixture and the mass is wet mixed. The wet mass is dried in an oven at 50°C. The prepared granulation is milled
5 through sieve 1 mm in an oscillating mill equipment. The coated pellets with an over-coating layer, the prepared H₂ receptor antagonist granules, cross-linked polyvinylpyrrolidone and sodium stearyl fumarate are mixed and compressed into tablets using a tableting machine equipped with oval punches. The amount of omeprazole in each tablet is approx. 10 mg and the amount of cimetidine hydrochloride is approx. 100 mg.

10

By a slight modification this multiple-unit tablet form can be made to comprise an antacid agent (instead of microcrystalline cellulose, 300 mg; microcrystalline cellulose, 100 g; calcium carbonate, 100 mg; magnesium oxide, 100 mg; all other constituents, except water, in the amounts given above).

15

EXAMPLE 2. Three-layered tableted dosage form. The tablet comprises the acid-susceptible proton pump inhibitor omeprazole, a separating layer and a core layer comprising cimetidine hydrochloride. Batch size 1000 tablets.

20 First tablet layer

Cimetidine hydrochloride	200.0 g
Microcrystalline cellulose	250.0 g
PVP crosslinked	13.0 g
Sodium stearyl fumarate	3.8 g

25

Separating layer

Microcrystalline cellulose	80.0 g
----------------------------	--------

Second tablet layer30 Coated pellets comprising

omeprazole magnesium salt (same as in EXAMPLE 1)	78.3 g
Microcrystalline cellulose	174.0 g
PVP crosslinked	26.0 g
Sodium stearyl fumarate	1.4 g

The constituents of the first tablet layer are dry mixed and pre-compressed as a first layer in a tableting machine equipped with oval punches. Microcrystalline cellulose is filled on the top of the first layer to form a separating layer to the next layer. The constituents of the
5 second tablet layer are dry mixed and filled on top of the separating layer. The three layers are compressed into a three-layer tablet, which may be coated by a tablet coating layer. The amount of omeprazole is approx. 10 mg and that of cimetidine hydrochloride approx. 200 mg per tablet.

10 **EXAMPLE 3. Capsule dosage form.** No. 1 hard gelatin capsules (16) (Fig. 5; volume 0.48 ml) were filled with extended release-coated omeprazole pellets (15) containing 20 mg omeprazole (as prepared in EXAMPLE 1) and a dry mixture 14 of commercially available famotidine 20 mg and closed.

15 **EXAMPLE 4. Divided powder/pellet formulation.** Extended release pellets containing 15 mg lansoprazole (as prepared in analogy with EXAMPLE 1) and the famotidine preparation were dry mixed with citric acid. Single dose portions thereof containing 10 mg each of lansoprazole and famotidine hydrochloride and 200 mg powdery citric acid were dry packed in plastic laminate. The composition is intended to be poured into 20 ml of
20 water, stirred for a short time, and swallowed.

EXAMPLE 5. Multiple-unit capsule dosage form. The capsule comprises magnesium omeprazole and famotidine hydrochloride. For extended release coating layer, see US6274173, Example 1-4, the information under which is hereby incorporated as reference.
25 For enteric coating layer and over-coating layer, see WO 97/25066, page 22-23 under respective headings, the information under which is hereby incorporated by reference.

Magnesium omeprazole is mixed with microcrystalline cellulose spheres to an ordered mixture. The ordered mixture is coated with an extended release layer, consisting of
30 polyvinyl acetate, micronised lactose, propylene glycol and ammonia (25 %) in a fluid bed apparatus. These extended release pellets were the coated with an enteric coating layer consisting of methacrylic acid copolymer, mono- and diglycerides, triethyl citrate and polysorbate in a fluid bed apparatus. The extended release/enteric coated ordered units is then over-coated with a water suspension containing famotidine hydrochloride,

hydroxypropylmethyl cellulose and magnesium stearate in a fluid bed apparatus. The extended release/enteric coated ordered mixture with an over-coating layer was filled into hard gelatin capsules. The amount of omeprazole is approx. 10 mg and that of famotidine hydrochloride approx. 20 mg per capsule.

5

EXAMPLE 6. Multiple-unit tableted dosage form. The tablet comprises magnesium omeprazole and cimetidine hydrochloride. Magnesium omeprazole is mixed with mannitol granules to an ordered mixture which is coated with both an extended release coating layer and an enteric coating layer as described in EXAMPLE 5. Cimetidine hydrochloride is granulated as described in EXAMPLE 1. The coated ordered mixture comprising magnesium omeprazole, the cimetidine granules and excipients are dry mixed and compressed into tablets. The amount of omeprazole in each tablet is approx. 10 mg and that of cimetidine is approx. 100 mg.

15 **EXAMPLE 7. Multiple-unit tableted dosage form for instant release of H₂ receptor antagonist and colon extended release of proton pump inhibitor.** The tablet comprises magnesium omeprazole and cimetidine hydrochloride.

Core material

20 Omeprazole magnesium salt 120 g
Sugar sphere seeds 150 g
Hydroxypropyl methylcellulose 18 g
Polysorbate 80 2.4 g
Water purified 562 g

25

Suspension layering was performed in a fluid bed apparatus. Omeprazole magnesium salt was sprayed onto sugar sphere seeds from a water suspension containing the dissolved binder and polysorbate 80. The size of sugar sphere seeds were in the range of 0.25 to 0.35 mm.

30

Extended release layer

Core material (acc. to above) 200 g
Eudragit® RTM 100g
Hydroxypropyl cellulose 10g

Delayed release layer

Pellets covered with extended release layer (acc. to above) 250 g

Eudragit® FS 30 D 100g

- 5 The prepared core material was covered with both an extended release layer and a delayed release layer in a fluid bed apparatus with commercially available water-based suspensions, Eudragit® RTM and Eudragit® FS 30 D, respectively.

Enteric coating layer

- 10 Pellets covered with both a delayed release and extended release layer (acc. to above) 250 g

Methacrylic acid copolymer (30% suspension) 333.7 g

Triethyl citrate 30 g

Mono- and diglycerides (NF) 5 g

Polysorbate 80 0.5 g

- 15 Water purified 196 g

- The enteric coating layer consisting of methacrylic acid copolymer, mono-and diglycerides, triethyl citrate and polysorbate was sprayed onto the pellets covered with extended/delayed release layers in a fluid bed apparatus. The enteric coating layered pellets were classified by sieving.
- 20

Tablets

Prepared pellets comprising omeprazole Mg-salt 63.7 g

Cimetidine hydrochloride 65.0 g

- 25 Calcium carbonate 123.9 g

Magnesium hydroxide 123.9 g

Potato starch 52.2 g

Water purified 435 g

Microcrystalline cellulose 175 g

- 30 Polyvidone crosslinked 50.0 g

Sodium stearyl fumarate 6.0 g

A small amount of the potato starch was dissolved in hot purified water to form the granulation liquid. Cimetidine hydrochloride, calcium carbonate, magnesium hydroxide and

potato starch were dry-mixed. The granulation liquid was added to the dry mixture and the mass was wet-mixed.

5 The wet mass was dried in a steamoven at 40 DEG C. The prepared granulation was milled through sieve 1 mm in an oscillating mill equipment.

The multiple coated layered pellets, prepared granules, polyvidone crosslinked, microcrystalline cellulose and sodium stearyl fumarate were mixed and compressed into tablets using a tableting machine equipped with 9.times.20 mm oval punches. The amount
10 of omeprazole in each tablet was approx. 20 mg and the same amount was used for cimetidine hydrochloride.

Tablet hardness was measured to 30N.

Optionally the obtained tablets were covered with a tablet coating layer.
15

CLAIMS

1. An oral pharmaceutical dosage form comprising pharmacologically effective amounts of an acid-susceptible proton pump inhibitor or a salt thereof and an H2 receptor antagonist or a salt thereof, and at least one pharmaceutically acceptable excipient(s) which results in a delayed release and/or extended release of the acid-susceptible proton pump inhibitor or the salt thereof, and said H2 receptor antagonist or the salt thereof is included in such a way that it is rapidly released from said dosage form.
2. The dosage form of claim 1, wherein the acid-susceptible proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, leminoprazole, their pharmaceutically acceptable salts, enantiomers and salts of enantiomers.
3. The dosage form of claim 1 or 2, comprising from 1 mg to 100 mg of the acid-susceptible proton pump inhibitor or a salt thereof per single dose.
4. The dosage form of claim 1, wherein the H2 receptor antagonist is selected from cimetidine, ranitidine, nizatidine and famotidine, their pharmaceutically acceptable salts, isomers and salts of isomers.
5. The dosage form of claim 4, comprising from 1 mg to 800 mg of H2 receptor antagonist or salt thereof.
6. The dosage form of any one of claims 1-5, wherein the excipient(s) exerts the release controlling activity in the form of a membrane applied onto a core comprising the acid-susceptible proton pump inhibitor or a salt thereof, or in the form of a matrix system where the acid-susceptible proton pump inhibitor or a salt thereof is incorporated into the excipient(s).
7. The dosage form of any one of claims 1-6, wherein the H2 receptor antagonist or a salt thereof forms an outer layer applied onto a core comprising the acid-susceptible proton pump inhibitor or a salt thereof and excipients, wherein the core forms a matrix or

membrane system, capable of delayed and/or extended release of the acid-susceptible proton pump inhibitor or a salt thereof.

8. The dosage form of any one of claims 1-7, wherein the excipient(s) used to form
5 the membrane or matrix are inert or lipid.

9. The dosage form of claim 8, wherein the inert excipient(s) are non-polymeric-or
polymeric materials such as calcium phosphate, ethyl cellulose, methacrylate copolymer,
polyamide, polyethylene, polyvinyl alcohol or polyvinyl acetate.

10

10. The dosage form of claim 8, wherein the lipid excipient(s) are non-polymeric-or
polymeric materials such as carnauba wax, cetyl alcohol, hydrogenated vegetable oils,
microcrystalline waxes, mono- and triglycerides, polyethylene glycol or polyethylene
glycol monostearate.

15

11. The dosage form of claim 9 or 10, wherein additional hydrophilic excipient(s) are
used, such as alginates, carbopol, gelatin, hydroxypropyl cellulose, hydroxypropyl
methylcellulose or methylcellulose.

20

12. The dosage form of any one of claims 6-11, wherein an enteric coating layer is
applied onto the membrane or matrix system and, optionally, a layer separating the enteric
coating from the membrane or matrix system.

25

13. The dosage form of any of claims 6-12, wherein an alkaline-reacting substance is
admixed together with the acid-susceptible proton pump inhibitor or the salt thereof.

30

14. The dosage form of any one of claims 1-13, wherein said pharmacologically
effective amounts are amounts capable to raise gastric pH to above 4 within two hours after
administration and to keep it above 4 for at least 4 hours.

15. The dosage form of claim 14, wherein said amounts are capable to keep gastric
pH above 4 for at least 8 hours.

16. The dosage form of claim 14 or 15, wherein said pharmacologically effective amounts are amounts capable to raise gastric pH to above 3 within 2 hours from administration and to keep it above 3 for at least 4 hours.

5 17. The dosage form of claim 16, wherein said amounts are amounts capable to keep gastric pH above 3 for at least 8 hours.

18. The dosage form of any one of claims 1-17, comprising from 100 mg to 1000 mg of antacid agent and/or alginate.

10

19. The dosage form of claim 18, wherein the antacid agent comprises one or several of aluminum hydroxide, calcium carbonate, magnesium carbonate, basic magnesium carbonate, magnesium hydroxide, magnesium oxide, sodium hydrogen carbonate.

15 20. The dosage form of any one of claims 1-19, wherein the acid-susceptible proton pump inhibitor or a salt thereof and excipients, together forming a membrane or matrix system, are present in the form of a multiple-unit system consisting of a plurality of small units, consisting of pellets, granules or beads.

20 21. The dosage form of claim 20, wherein the small units in the multiple-unit system also contain an outer layer of a H2 receptor antagonist or a salt thereof.

22. The dosage form of claim 20, wherein the small units are dispersed in a H2 receptor antagonist or a salt thereof, optionally admixed with pharmaceutically acceptable
25 excipients, such as disintegrant(s).

23. The dosage form of any one of claims 1-19, comprising two halves, one of which comprising an acid-susceptible proton pump inhibitor or a salt thereof in admixture with excipients capable of forming a matrix or membrane system and the other half comprising
30 an H2 receptor antagonist or a salt thereof, optionally admixed with pharmaceutically acceptable excipients, such as disintegrant(s).

24. A capsule according to any one of claims 1-23.

25. A divided powder/pellet formulation according to any one of claims 1-23.

26. A tablet according to any one of claims 1-23.

5 27. The tablet of claim 26, being divisible.

28. The tablet of claim 26, being dispersible in water.

29. The tablet of claim 28, comprising a disintegrant.

10

30. A method for the manufacture of an oral pharmaceutical dosage form comprising pharmacologically effective amounts of an acid-susceptible proton pump inhibitor or a salt thereof and an H₂ receptor antagonist or a salt thereof, and at least one pharmaceutically acceptable excipient which results in a delayed release and/or extended release of the acid-susceptible proton pump inhibitor or the salt thereof, and said H₂ receptor antagonist or the salt thereof is included in such a way that it is rapidly released from said dosage form, said method comprising forming a first layer comprising said acid-susceptible proton pump inhibitor or salt thereof, and forming a coating thereon of said at least one excipient, and forming a second layer comprising said H₂ receptor antagonist or salt thereof surrounding said first layer and said coating, and subsequently formulating the combined product of said first layer, said coating and said second layer into an oral pharmaceutical dosage form.

31. A method according to claim 30, wherein said acid-susceptible proton pump inhibitor is enclosed in said least one excipient, said excipient forming a lipid or water-insoluble matrix.

32. A method according to claim 30 or 31, wherein said first layer is formed to pellets, which are subsequently coated with said at least one excipient and are subsequently mixed with a carrier comprising said H₂ receptor antagonist or salt thereof.

30

33. A method according to claim 32, wherein said carrier comprises a pharmacological disintegrant.

34. A method according to any one of claims 30-33, wherein said combined product is formulated into a tablet.

35. A method according to any one of claims 30-33, wherein said combined product is formulated into a capsule capable of disintegrating in gastro-intestinal fluids.

36. A method according to any one of claims 30-35, wherein said oral pharmaceutical dosage form is provided with an enteric coating.

37. A method according to any one of claims 30-36, wherein said acid-susceptible proton pump inhibitor is selected from the group consisting of lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, lemiprazole and their pharmaceutically acceptable salts, enantiomers and salts of enantiomers.

38. A method according to any one of claims 30-36, wherein said H₂ receptor antagonist is selected from the group consisting of cimetidine, ranitidine, nizatidine, famotidine and their pharmaceutically acceptable salts, isomers and salts of isomers.

39. Use of an oral pharmaceutical dosage form according to any one of claims 1-29, for the manufacture of a medicament for the treatment of conditions associated with the secretion of gastric acid.

40. Use of an oral pharmaceutical dosage form according to any one of claims 1-29 in association with one or more antibiotic agents for the eradication of *Helicobacter pylori*.

41. A method of treating a condition associated with the secretion of gastric acid, wherein an oral pharmaceutical dosage form according to any one of claims 1-29 is administered in a therapeutically effective amount to an individual human or animal afflicted with said condition.

42. A method for treating an infection by *Helicobacter pylori*, wherein an oral pharmaceutical dosage form according to any one of claims 1-29 in association with one or more antibiotic agents effective against *H. pylori* is administered in a therapeutically effective amount to an individual or human afflicted with said infection.

43. A method according to claim 41 or 42, wherein said oral pharmaceutical dosage form is administered concomitantly as two separate oral dosage forms, one comprising a pharmacologically effective amount of said acid-susceptible proton pump inhibitor or salt thereof, and the other comprising a pharmacologically effective amount of said H2 receptor antagonist or salt thereof.

44. A method according to any one of claims 41-43, comprising a dose regimen capable of maintaining gastric pH above 4 for at least 95% of a time period starting at 2 hours from the administration of the first dose and extending until 6 hours from the administration of the last dose.

45. A method according to claim 44, wherein said time period is at least one week.

46. A method according to claim 44, wherein said time period is at least two weeks.

47. A method according to claim 44, wherein said time period is at least four weeks.

48. A method according to any one of claims 41-43, comprising a dose regimen capable of maintaining gastric pH above 3 for at least 95% of a time period starting at 2 hours from the administration of the first dose and extending until 6 hours from the administration of the last dose, in particular for at least four weeks.

1/1

Fig. 1




Fig. 2




Fig. 3





Fig. 4



INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001598

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 45/06, A61K 9/00, A61P 1/04 // A61K 31/4439, A61K 31/4164, A61K31/341, A61K31/426

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI DATA, EPO-INTERNAL, PAJ, CA DATA, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02083132 A1 (DIABACT AB), 24 October 2002 (24.10.2002) --	1-48
Y	US 6183776 A (HELENE DEPUI ET AL), 6 February 2001 (06.02.2001) --	1-48
Y	WO 9725065 A1 (ASTRA AKTIEBOLAG), 17 July 1997 (17.07.1997) --	1-48
Y	WO 9311750 A1 (FUISZ TECHNOLOGIES LTD.), 24 June 1993 (24.06.1993) --	1-48

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 15 January 2004	Date of mailing of the international search report 22 -01- 2004
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Ingrid Eklund/EÖ Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001598

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Br. J. Clin. Pharmac., Volume 31, 1991, Tommy Andersson et al: "Influence of acid secretory status on absorption of omeprazole from enteric coated granules", page 275-278 --	1-48
Y	Canadian pharmaceutical journal, Volume 135, no. 7, 2002, Doret Cheng: "Combined use of proton pump inhibitors and histamine-H2 receptor antagonists for GERD: What is the rationale?", page 27 - page 45 --	1-48
Y	Gastroenterology, Volume 115, 1998, Paolo L. Peghini et al: "Ranitidine Controls Nocturnal Gastric Acid Breakthrough on Omeprazole: A Controlled Study in Normal Subjects", page 1335 - page 1339 --	1-48
Y	Baillière's Best Practice & Research Clinical Gastroenterology, Volume 15, no. 3. 2001, Philip O. Katz MD et al: "Histamine receptor antagonists; proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease", page 371 - page 384 --	1-48
A	US 5204118 A (WILLIAM J. GOLDMAN ET AL), 20 April 1993 (20.04.1993) --	1-48
A	WO 9904773 A2 (MERCK & CO., INC.), 4 February 1999 (04.02.1999) -- -----	1-48

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/12/2003

International application No.

PCT/SE 2003/001598

WO	02083132	A1	24/10/2002	AU	7476501 A	02/01/2002
				BR	0111900 A	13/05/2003
				CA	2411553 A	27/12/2001
				EP	1307192 A	07/05/2003
				NO	20026085 A	18/12/2002
<hr/>						
US	6183776	A	06/02/2001	AT	228009 T	15/12/2002
				AU	712669 B	11/11/1999
				AU	1324197 A	01/08/1997
				BR	9607350 A	30/12/1997
				CA	2213996 A	17/07/1997
				CN	1080125 B	06/03/2002
				CN	1183047 A	27/05/1998
				CZ	9702747 A	18/03/1998
				DE	69624907 D,T	21/08/2003
				DK	813424 T	10/03/2003
				EE	4002 B	15/04/2003
				EE	9700192 A	16/02/1998
				EP	0813424 A,B	29/12/1997
				SE	0813424 T3	
				ES	2185817 T	01/05/2003
				HK	1001763 A	00/00/0000
				HK	1017992 A	00/00/0000
				HU	9904024 A	28/05/2000
				IL	121651 D	00/00/0000
				JP	11501950 T	16/02/1999
				NO	974071 A	17/10/1997
				NZ	325977 A	25/02/1999
				PL	322175 A	19/01/1998
				PT	813424 T	31/03/2003
				RU	2179453 C	20/02/2002
				SE	9600071 D	00/00/0000
				SK	116997 A	06/05/1998
				TR	9700916 T	00/00/0000
				TW	464514 B	00/00/0000
				WO	9725066 A	17/07/1997
				ZA	9610935 A	08/07/1997
				BR	9708915 A	03/08/1999
				DE	19781732 T	25/03/1999
				EP	0900455 A	10/03/1999
				JP	2000509923 T	02/08/2000
				SE	506575 C	12/01/1998
				SE	9601737 A	08/11/1997
				WO	9742681 A	13/11/1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/12/2003

International application No.

PCT/SE 2003/001598

WO	9725065	A1	17/07/1997	AT	228010	T	15/12/2002
				AU	702862	B	11/03/1999
				AU	712572	B	11/11/1999
				AU	1324097	A	01/08/1997
				AU	4637396	A	21/08/1996
				BR	9607344	A	30/12/1997
				CA	2214033	A	17/07/1997
				CN	1183049	A	27/05/1998
				CZ	9702808	A	15/04/1998
				DE	69624910	D, T	04/09/2003
				DK	814840	T	24/02/2003
				EE	9700195	A	16/02/1998
				EP	0807335	A	19/11/1997
				EP	0814840	A, B	07/01/1998
				SE	0814840	T3	
				ES	2185816	T	01/05/2003
				FI	973144	A	18/09/1997
				HU	9904094	A	28/06/2000
				IL	121652	A	10/03/2002
				JP	10513322	T	15/12/1998
				JP	11501949	T	16/02/1999
				NO	974070	A	06/10/1997
				NZ	325976	A	25/02/1999
				PL	322176	A	19/01/1998
				PT	814840	T	30/04/2003
				SE	9600072	D	00/00/0000
				SK	117097	A	03/06/1998
				TR	9700917	T	00/00/0000
				US	6132771	A	17/10/2000
				ZA	9610938	A	08/07/1997
<hr/>							
WO	9311750	A1	24/06/1993	AU	3328193	A	19/07/1993
				CA	2125579	A	24/06/1993
				DE	69231281	D, T	01/03/2001
				DK	661966	T	16/10/2000
				EP	0661966	A, B	12/07/1995
				SE	0661966	T3	
				JP	7502276	T	09/03/1995
				PL	170554	B	31/12/1996
				US	5622717	A	22/04/1997
				US	5651987	A	29/07/1997
				US	5811123	A	22/09/1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/12/2003

International application No.

PCT/SE 2003/001598

US	5204118	A	20/04/1993	AT	101515	T	15/03/1994
				AU	646230	B	17/02/1994
				AU	6568990	A	09/05/1991
				CA	2028746	A,C	03/05/1991
				DE	69006684	D,T	09/06/1994
				EP	0426479	A,B	08/05/1991
				ES	2057439	T	16/10/1994
				GR	1002097	B	28/12/1995
				GR	90100786	A	17/04/1992
				IE	64953	B	20/09/1995
				IE	903946	A	08/05/1991
				IN	171746	A	26/12/1992
				JP	3206052	A	09/09/1991
				NZ	235877	A	25/09/1992
				PT	95753	A	30/09/1991
				US	5417980	A	23/05/1995
				ZA	9008775	A	29/07/1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/12/2003

International application No.

PCT/SE 2003/001598

WO	9904773	A2	04/02/1999	AT	209037	T	15/12/2001
				AU	8493698	A	16/02/1999
				BG	104093	A	31/10/2000
				BR	9810779	A	25/07/2000
				CA	2294595	C	21/08/2001
				CA	2349733	A	04/02/1999
				CA	2349744	A	04/02/1999
				DE	69803291	D,T	08/08/2002
				DK	998292	T	13/05/2002
				EE	200000040	A	16/10/2000
				EP	0998292	A,B	10/05/2000
				SE	0998292	T3	
				EP	1132088	A	12/09/2001
				EP	1151752	A	07/11/2001
				EP	1175903	A	30/01/2002
				EP	1175904	A	30/01/2002
				ES	2164447	T	16/02/2002
				GB	9717590	D	00/00/0000
				HK	1024166	A	00/00/0000
				HR	20000035	A	28/02/2001
				HU	0004653	A	28/04/2001
				IL	133535	D	00/00/0000
				IL	141218	D	00/00/0000
				IL	143264	D	00/00/0000
				JP	2002502433	T	22/01/2002
				NO	20000323	A	20/03/2000
				NZ	501807	A	28/02/2003
				PL	338635	A	06/11/2000
				PT	998292	T	29/04/2002
				SI	998292	T	00/00/0000
				SK	932000	A	12/09/2000
				TR	200000145	T	00/00/0000
				GB	9717850	D	00/00/0000
				CN	1265035	T	30/08/2000
				US	5994329	A	30/11/1999
				US	6015801	A	18/01/2000
				US	6225294	B	01/05/2001
				US	6333316	B	25/12/2001
				US	6432932	B	13/08/2002
				US	6465443	B	15/10/2002
				US	6544967	B	08/04/2003
				US	2001001306	A	17/05/2001
				US	2001002395	A	31/05/2001
				US	2001018431	A	30/08/2001
				US	2002010161	A	24/01/2002
				US	2002065252	A	30/05/2002
				US	2002102681	A	01/08/2002
				US	2002102682	A	01/08/2002
				US	2002110884	A	15/08/2002
				US	2003032629	A	13/02/2003
				US	2003212047	A	13/11/2003
				ZA	9806479	A	22/01/1999

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01598

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **40-48**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet*
2. ☒ Claims Nos.: **1-39**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet**
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01598

Box No. IV Text of the abstract (Continuation of Item 5 of the first sheet)

☆

Claims 40-48 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

☆☆

Present claims 1-39 relate to dosage forms, and to methods for the production of these dosage forms, defined by reference to desirable properties of the dosage forms, namely "inhibition of acid susceptible proton pumps", "antagonism of H₂ histamine receptors", "pharmacologically effective amounts", "delayed release and/or extended release", and "rapidly released". The claims cover all dosage forms having these properties and all methods for the production of dosage forms having these properties, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such dosage forms and methods.

Independent of the above reasoning, the claims 1-39 also lack clarity (Article 6 PCT). An attempt is made to define the products by reference to a result to be achieved. This lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Specifically, the terms "acid susceptible proton pump inhibitor" and "H₂ receptor antagonist" apparently relate to a very large amount of different compounds, which do not necessarily have to be defined as acid susceptible proton pump inhibitors or H₂ receptor antagonists, thus rendering it impossible to perform a complete search.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely the present claim 2 in combination with the present claim 4, as well as the present claim 37 in combination with the present claim 38.